In chronic myeloid leukemia (CML), imatinib resistance has been associated with changes in BCR-ABL1 and intracellular drug concentration, controlled by SLC and ABC transporters. Here, CCL21 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.